Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177lu/90y-dotatoc and 213bi-dotatoc radiopeptide therapy / Giesel, F. L., Flechsig, P., Kuder, T., Schwartz, L., Wulfert, S., Zechmann, C., Bruchertseifer, F., Haberkorn, U., Kratochwil, C. (2013)
web address of the page http://jnas.nbuv.gov.ua/article/UJRN-0000072246
Experimental Oncology  А - 2020 /  Issue (2013, Vol. 35, № 2)
Giesel F. L., Flechsig P., Kuder T., Schwartz L., Wulfert S., Zechmann C., Bruchertseifer F., Haberkorn U., Kratochwil C.
Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177lu/90y-dotatoc and 213bi-dotatoc radiopeptide therapy
Cite:
Giesel, F. L., Flechsig, P., Kuder, T., Schwartz, L., Wulfert, S., Zechmann, C., Bruchertseifer, F., Haberkorn, U., Kratochwil, C. (2013). Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177lu/90y-dotatoc and 213bi-dotatoc radiopeptide therapy. Experimental Oncology, 35 (2), 122-126. http://jnas.nbuv.gov.ua/article/UJRN-0000072246 | |
|
|
PDF